查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587563

特發性肺纖維化治療市場規模、佔有率、趨勢分析報告：按藥物類別、給藥途徑、分銷管道、地區和細分市場預測，2025-2030 年

Idiopathic Pulmonary Fibrosis Treatment Market Size, Share & Trends Analysis Report By Drug Class (Pirfenidone, Nintedanib), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

特發性肺纖維化治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球特發性肺纖維化治療市場規模預計將達到54.6億美元，2025年至2030年複合年成長率為6.8%。

公司加強研發舉措以及吸菸人口的快速增加預計將推動成長。

製造商採取更多舉措來開發具有新穎機制的產品，預計將推動 IPF 治療市場的成長。例如，Fibrogen 目前正在開發 pamrevlumumab，這是一種針對結締組織生長因子的單株抗體。 pamrevlumumab 的 III 期試驗預計將於 2019 年上半年開始。該藥物已獲得食品藥物管理局（FDA）的快速通道指定。

預計老化將對幾乎所有部門（包括醫療保健部門）產生深遠的社會、經濟和政治影響。由於老年人口的增加，需要長期照護的各種疾病的發生率將會增加。此外，中國和日本等具有大量開拓機會的國家老年人口的增加預計將在預測期內推動市場成長。

吸菸人口的急劇增加是可能對市場成長產生正面影響的主要促進因素之一。根據美國FDA 和疾病管制與預防中心 (CDC) 的數據，2018 年有超過 360 萬名高中生和中學生是電子煙使用者。自去年以來，這個數字增加了150萬人。電子煙的普及性有望帶動IPF的發展。

特發性肺纖維化治療市場報告亮點：

  • Pirfenidone佔據市場主導地位，2024 年市佔率將達到 43.0%。
  • 口服藥物引領市場，2024年銷售佔有率為69.3%。與注射療法相比，Pirfenidone和尼達尼布可提高患者的依從性。
  • 2024年，醫院藥局的銷售額佔比最大，為62.9%。這是因為醫院配備了先進的診斷工具，可以準確診斷和監測IPF，有利於及時開始治療。
  • 2024年，美國將因其較高的市場滲透率和IPF認知度而處於領先地位。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章特發性肺纖維化治療市場變數、趨勢、範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章特發性肺纖維化治療市場：藥物類別的商業分析

  • 2024 年及 2030 年藥品類別市場佔有率
  • 藥品類別細分儀表板
  • 2018-2030 年按藥物類別分類的市場規模、預測與趨勢分析
  • Pirfenidone
  • 尼達尼布
  • 干擾素γ1b
  • 其他

第5章特發性肺纖維化治療市場：給藥途徑的商業分析

  • 2024 年及 2030市場佔有率給藥途徑途徑
  • 途徑細分儀表板
  • 2018-2030 年按管理途徑的市場規模、預測與趨勢分析
  • 口服
  • 注射

第6章特發性肺纖維化治療市場：通路業務分析

  • 2024 年及 2030 年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 2018-2030 年按分銷管道分類的市場規模、預測與趨勢分析
  • 醫院藥房
  • 零售藥房
  • 其他

第7章特發性肺纖維化治療市場：按藥物類別分類的區域估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 按國家/地區分類，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類，2018-2030
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 按國家/地區分類，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 參與者概覽
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • F. Hoffmann-La Roche Ltd
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Medicinova, Inc
    • Merck &Co., Inc.
    • Galapagos NV
    • Novartis AG
    • Fibrogen, Inc.
Product Code: GVR-3-68038-119-1

Idiopathic Pulmonary Fibrosis Treatment Market Growth & Trends:

The global idiopathic pulmonary fibrosis treatment market size is expected to reach USD 5.46 billion by 2030, registering a CAGR of 6.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing R&D initiatives undertaken by companies and surge in cigarette smoking population are anticipated to boost the growth.

Rise in the initiatives undertaken by manufacturers to develop products with novel mechanisms is anticipated to fuel the IPF treatment market growth. For instance, FibroGen, Inc., is currently developing a drug, pamrevlumab - a monoclonal antibody that targets the connective tissue growth factor. The phase III trials of pamrevlumab are expected to be initiated in the first half of 2019. The drug has received fast track designation from the Food and Drug Administration (FDA).

An aging population can be expected to have far-reaching social, economic, and political implications on nearly all the sectors including the healthcare sector. An associated consequence of an increase in the geriatric population will be an increase in the incidences of various medical conditions requiring long-term care. Moreover, the growing geriatric population base in countries with large untapped opportunities such as China and Japan is anticipated to drive the market growth during the forecast period.

The dramatic increase in cigarette smoking population is one of the major drivers likely to have a positive impact on market growth. According to the U.S. FDA and Centers for Disease Control and Prevention (CDC), in 2018, more than 3.6 million high and middle school students were existing e-cigarette users. The number increased by 1.5 million since the last year. The uptake in the use of e-cigarette is expected to lead to the incidence of IPF.

Idiopathic Pulmonary Fibrosis Treatment Market Report Highlights:

  • Pirfenidone dominated the market and accounted for a share of 43.0% in 2024.
  • Orally administered medications led the market with a revenue share of 69.3% in 2024. Pirfenidone and nintedanib enhance patient compliance compared to injectable therapies.
  • Hospital pharmacies held the largest revenue share 62.9% in 2024, as hospitals are equipped with advanced diagnostic tools for accurate IPF diagnosis and monitoring, facilitating timely treatment initiation.
  • U.S. led in 2024 due to high market penetration and high awareness pertaining to IPF

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Idiopathic Pulmonary Fibrosis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Idiopathic Pulmonary Fibrosis Treatment Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Pirfenidone
    • 4.4.1. Pirfenidone Market, 2018 - 2030 (USD Million)
  • 4.5. Nintedanib
    • 4.5.1. Nintedanib Market, 2018 - 2030 (USD Million)
  • 4.6. Interferon Gammato1b
    • 4.6.1. Interferon Gammato1b Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Idiopathic Pulmonary Fibrosis Treatment Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2024 & 2030
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market, 2018 - 2030 (USD Million)
  • 5.5. Injectable
    • 5.5.1. Injectable Market, 2018 - 2030 (USD Million)

Chapter 6. Idiopathic Pulmonary Fibrosis Treatment Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Idiopathic Pulmonary Fibrosis Treatment Market: Regional Estimates & Trend Analysis by Drug Class, Route Of Administration, and Distribution Channel

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. F. Hoffmann-La Roche Ltd
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Boehringer Ingelheim International GmbH
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Bristol-Myers Squibb Company
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Medicinova, Inc
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Merck & Co., Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Galapagos NV
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Novartis AG
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Fibrogen, Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global idiopathic pulmonary fibrosis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Global idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 Global idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 North America idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 North America idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 U.S. idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 13 U.S. Idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 Canada idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 Canada idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16 Canada idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Mexico idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Mexico idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Europe idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Europe idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 UK idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 26 UK Idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27 Germany idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 Germany idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 29 Germany idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 France idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 31 France idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 France Idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Italy idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Italy idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 Italy idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 37 Spain idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 38 Spain idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Norway idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 Norway idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 Norway Idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Denmark idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 43 Denmark idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 Denmark idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Sweden idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 Sweden idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Sweden idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Japan idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 Japan idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 54 Japan idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 China idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 China idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57 China idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 India idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 India idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 India idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Australia idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Australia idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63 Australia idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 South Korea idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 65 South Korea idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66 South Korea idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 68 Thailand idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 69 Thailand idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 72 Latin America idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 Latin America idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 75 Brazil idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Brazil idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 78 Argentina idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 79 Argentina idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 85 South Africa idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86 South Africa idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 UAE idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 91 UAE idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 92 UAE idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 94 Kuwait idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95 Kuwait idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Idiopathic pulmonary fibrosis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug class and route of administration outlook (USD Million)
  • Fig. 10 Distribution channel outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Idiopathic pulmonary fibrosis treatment market dynamics
  • Fig. 13 Idiopathic pulmonary fibrosis treatment market: Porter's five forces analysis
  • Fig. 14 Idiopathic pulmonary fibrosis treatment market: PESTLE analysis
  • Fig. 15 Idiopathic pulmonary fibrosis treatment market: Drug class segment dashboard
  • Fig. 16 Idiopathic pulmonary fibrosis treatment market: Drug class market share analysis, 2024 & 2030
  • Fig. 17 Pirfenidone market, 2018 - 2030 (USD Million)
  • Fig. 18 Nintedanib market, 2018 - 2030 (USD Million)
  • Fig. 19 Interferon Gammato1b market, 2018 - 2030 (USD Million)
  • Fig. 20 Others market, 2018 - 2030 (USD Million)
  • Fig. 21 Idiopathic pulmonary fibrosis treatment market: Route of administration segment dashboard
  • Fig. 22 Idiopathic pulmonary fibrosis treatment market: Route of administration market share analysis, 2024 & 2030
  • Fig. 23 Oral market, 2018 - 2030 (USD Million)
  • Fig. 24 Injectable market, 2018 - 2030 (USD Million)
  • Fig. 25 Idiopathic pulmonary fibrosis treatment market: Distribution channel segment dashboard
  • Fig. 26 Idiopathic pulmonary fibrosis treatment market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 27 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 28 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 Idiopathic pulmonary fibrosis treatment market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 France country dynamics
  • Fig. 46 France idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 Asia Pacific idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 China country dynamics
  • Fig. 61 China idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 India country dynamics
  • Fig. 63 India idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 Latin America idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 75 MEA idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework